Smary The contribution of host-derived growth factors to tumour growth in vivo was studied using the transplantable murine mammary carcinoma, MTI, grown in syngeneic mice. Promotion of growth of the mammary carcinoma by a factor(s) from the host was cvient in experiments in which the carci cels were inoculated intaperitoneally. In this environment, tumours develop as multiple sold noduks, each probably arisng from an individual cell or a small cluster of cels Tumour growth was found to occur in the peritoneal cavity following inoculation of 10' cells, but an inoculum of as few as ten cells grew if a leucocyte-rich exudate had first been induced. To determine which host-derived growth factors might contrnbute to growth of MT1, extracts of the tumour were first examined for growth factor activity. Fractionation of tumour extracts by either ion-exchange chromatography or gel filtration revealed several peaks of mitogenic activity, but none of this could be attributed to epidermal growth factor (EGF). Accordingly, an anti-EGF antibody was tested as a putative inhibitor of tumour growth as any effect of this antibody could be ascribed to removal of EGF derived from the host The antibody was found to have potent anti-tumour activity when tested aganst MT1 tumours that had been inoculated into the peritoneal cavity. In contrast, the antibody had little effect on growth of the discrete tumour mass which formed when MTI was translanted subcutaneously. The results suggest that host-derived EGF contributes to establshment of microcolonies of MT1 carcnoma within the peritoneal cavity. This may be dimctly, by proding growth factors to supplment those produced by the tumour until it reaches a certain critical mass to sustain autocrine growth, or indirectly, by affecting the production of other growth-stimulatory factors or cytokines.
When grown in tissue culture, malignant cells generally require less exogenously added growth factors than their normal counterparts. This has led to the autocrine hypothesis, which proposes that cancer cells are able to sustain their own growth by synthesis of growth-stimulatory factors for which they possess appropriate cell-surface receptors (Sporn & Todaro, 1980) . Although there is now considerable evidence in support of this hypothesis, it is also apparent that the autocrine growth factors produced by cancer cells are not always suffiient to sustain maximal growth. Thus, in tissue culture, exogenously added growth factors such as epidemal growth factor (EGF) have been shown to stimulate growth of primary and metastatic tumour cells (Singletary et al., 1989) . Similarly, in vivo, studies on the sites of growth of tumours derived from blood-borne carcinoma or sarcoma cells have suggested that host-derived growth factors could be necessary for growth to occur from isolated (or small clusters of) tumour cells (Murphy et al., 1988) . The requirement for these factors may arise because diffuision lowers the effective local concentration of tumourderived growth factors, which may then be insufficient to induce division of the isolated cell (Alexander, 1987) . This problem of diffusion diminishes as the number of cells in close proximity increases (i.e. as the tumour grows). For an isolated cell to develop into a tumour, it is postulated that autocrine growth factor(s) need to be supplemented by hostderived factors.
Several lines of evidence have indicated an in vivo role for EGF in tumour development and progression. Thus, EGF has been found to enhance spontaneous mammary tumorigenesis (Kurachi et al., 1985) and to promote implantation and/or growth of spontaneous mammary tumours in mice (Tsutsumi et al., 1987; Inui et al., 1989) . In these studies, direct evidence for a role of host-derived EGF was obtained by use of mice in which the amount of EGF in blood had been reduced to low levels by surgical removal of the salivary gland (sialoadenectomy). In such mice, the growth of the tumour was reduced and the effects of sialoadenectomy could be reversed by the administration of EGF. In studies using a rat rhabdomyosarcoma, cell proliferation was stimulated by EGF and a role for EGF was further demonstrated in promotion of lung and lymphatic micrometastases (Breillout et al., 1989) . Growth of human A431 tumour cells, which express an unusually high number of EGF receptors in athymic mice, has also been shown to be stimulated by EGF, even though this growth factor is growth inhibitory (at nM concentrations) for A431 cells cultured in vitro (Ginsburg & Vonderhaar, 1985; Ozawa et al., 1987) .
In the present study, the wansplantable murine mammary carcinoma, MT1 (Barnett & Eccles, 1984) , was grown in the peritoneal cavity and used as a model for growth of isolated cancer cells. This is an appropriate system to test the contribution of host-derived EGF to growth because, as will be shown, MT1 does not synthesise any detectable EGF and its growth in vivo is promoted by host factors. The first of these investgations was reported at a meeting and published in an abstract (Blackler et al., 1988 MT] MTI tumour was homogenised in 1 M acetic acid containing 10 zg ml' I aproinin, 10 g ml ' leupepti, 17 g ml I phenyl methyl sulphonylfluoride (PMSF), 5 mM benzamidine, 5 tg ml1l pepstatin A, I mM N-a-p-tosyl-L-lysine chloromethyl ketone (TLCK) and 1 mM N-tosyl-L-phenylalanine chloromethyl betone (TPCK) and the extract clarified by centrifugation at 100,000g for 1 h at 4C. The supernatant was neutralised and dialysed against 25 mM Tris-HCl, pH 7.4, before fractionation by fast protein liquid anionexchange chromatography (FPLC) using a Mono-Q column. The column, which was equilibrated with 25 mM Tris-HCI, pH 7.4, was loaded with 2.5 mg of protein and bound protein eluted with a salt gradient from 0 to 0.5 M sodium chloride over 20 ml. Fractions (1 ml) were collected into tubes containing 100 ,Il of 1% BSA in phosphate-buffered saline (PBS) containing IO IU ml'l penicillin and I0 g ml' streptomycin and assayed as described below.
To enable detection of the membrane-bound, precursor were assayed for mitogenic activity and immunoreactive EGF as described below. Control experiments established that, at the dilution used, the salt or detergent concentrations present in the individual fractions did not significantly affect the mitogenic response of the cells to EGF.
Mitogenesis assay using density-arrestedfibroblasts Mitogenic activity was determined in a standard assay (Carpenter & Cohen, 1976 ) using confluent and quiescent human foreskin fibroblasts which had been obtained from a surgically removed foreskin and which were maintained in short-term culture for up to 20 passages; the assay was modified by use of ['2I]5'-iododeoxyuridine instead of [3Hjthymidine to facilitate sample processing for counting.
For assay, cells were seeded at 2.5 x 0I cells ml-' in 96-well trays and grown to confluence. After rendering the cells quiescent by incubation in 1% FBS/DMEM for 48 h, test substances (antibody, EGF, column fractions) were added to cells in serum-free DMEM-PBS (1:1) containing 1% bovine serum albumin, 4 pg ml-' insulin, 240 tg ml-' transferrin, 25 mM HEPES buffer, pH 7.4. Stimulation of DNA synthesis was assessed 23 h later by pulsing the cells for 2 h with 74 TBq mmol-') containing 5 jim 5-fluor-2'-deoxyuridine (FUdR). to a second ELISA tray to which EGF has been coupled as above. Following a 2 h incubation, antibody bound to the ELISA tray was detected using swine anti-rabbit immunoglobulins conjugated to horseradish peroxidase following the procedure outlined above. EGF contained in the samples was estimated by reference to a standard curve generated using mouse EGF (0-8 nM).
EGF was measured in column fractions using a sandwich ELISA which was approximately three times more sensitive than the competitive binding assay described above. In this assay, EGF was trapped by sheep anti-EGF IgG (1.5 jig) coupled to the wells of an ELISA tray. Bound EGF was detected by rabbit anti-EGF IgG (0.5#jgperwell) followed by a peroxidase-conjugated anti-rabbit IgG with colorimetric detection as above. EGF in samples was estimated by reference to a standard curve generated using mouse EGF (0-3.0 nM). responsible for the promotion of growth of MTI in the peritoneal cavity. However, to be able to determine whether EGF produced by the host contributed to proliferation of MT1, it was necessary to establish that the tumour did not produce this growth factor.
Initially, MT1 tumour tissue derived from subcutaneous tumour implants was extracted into acid as previously de- scribed (Koyama & Podolsky, 1989) . Separation of this extract by FPLC Mono-Q anion-exchange chromatography resulted in the detection of several peaks of mitogenic activity, however none of this activity could be blocked by anti-EGF IgG (Figure la) , nor could immunoreactive EGF be detected in crude extracts or the individual fractions (data not shown).
As EGF is also synthesised as a high molecular weight membrane-bound precursor which has been reported to be biologically active (Mroczkowski et al., 1989) , detergent extracts of MT1 tumour were also analysed to test if EGF occurred in the tumour in this form. Conditions for the extraction, partial purification by gel filtration and assay of the 150 kDa membrane-bound EGF precursor were establshed using mouse kidney. Even though kidney contains substantially lower levels of EGF than salivary glands, the developed procedure enabled detection of both the precursor and mature forms of EGF using both a sensitivie ELISA and the mitogenic assay of growth-arrested human foreskin fibroblasts (data not shown). Analysis of detergent extracts of MTI tumours by this procedure yielded fractions which demonstrated mitogenic activity in the standard assay; however, as found with the acidic extracts, the activity of these fractions could not be blocked by anti-EGF antibody ( Figure  lb) , nor could immunoreactive EGF be detected by ELISA. Moreover, the mitogenic activity was not blocked by an antibody directed against the EGF receptor (EGFR) (Figure  lb) , which blocks the mitogenic activity of both EGF and TGF-a. The nature of the mitogenic activity found in the extracts of MTI cells remains to be elucidated, but it was neither EGF nor its membrane-bound high molecular weight precursor. Given the lower limit of detection of our assays, we calculate that MTI tumour can only contain less than I pmol of EGF per g wet weight of tumour tissue.
Effect of EGF on growth of MTJ cells in vitro
Having established the absence of EGF in MTI tumours, the effect of EGF on in vitro growth of MTI cells was investigated. MTI cells, obtained by proteolytic disaggregation from the tumour, were readily established in vitro in 10% FBS/DMEM. The cells were adherent and exhibited cuboidal and fusiform morphologies as previously reported (Barnett & Eccles, 1984) . The MTI cells could not be grown in serumfree medium even when this had been supplemented with insulin and transferrin, but could be grown in medium containing serum which had been depleted of cationic growth factors such as platelet-derived growth factor (PDGF) by passage over a cation-exchange resin (cNBS). When MTI cells were cultured in 2% cNBS/DMEM, 1 nM EGF stimulated growth as evidenced by an increase in cell number (Figure 2) . The most marked effect of EGF was to reduce the lag phase preceding growth; once the cells had established growth, EGF provided no additional stimulus.
Inhibition of mitogenic activity of EGF by anti-EGF IgG and correlation with serwn sheep anti-EGF IgG levels To determine whether host-derived EGF contributed to establishment of MT] tumours grown in the peritoneal cavity, the effect of an anti-EGF IgG on tumour growth was determined. The IgG preparation used in the investigations described below was first tested for its ability to inhibit EGF-induced DNA synthesis. The mitogenic action of EGF was assayed by the standard procedure of initiating DNA synthesis in growth-arrested cultures of human foreskin fibroblasts. Figure 3 shows the degree of inhibition produced by increasing doses of the antibody on the stimulation of DNA synthesis induced by 1 riM EGF. Inhibition was complete using immune IgG at a concentration of lOggml-', whereas similar doses of control, non-immune, IgG had no effect on EGF-stimulated DNA synthesis. The anti-EGF antibody produced no inhibition of mitogenesis induced by TGF-x (see Figure 3) , even though these two ligands are structurally homologous and both bind to the EGF receptor. (Table IV) . Figure 3 shows that, in an in vitro assay, as little as l10pgml-' antibody is capable of inhibiting completely the mitogenic activity of 1 nM EGF, and Table III shows that, at 380 pgml', the antibody is able to inhibit concentrations of up to 32 nM EGF; for comparison, the serum level of EGF of untreated mice was less than the lowest level which our ELISA allowed us to determine, which was 0.12 nm. It is clear, therefore, that the circulating level of antibody was greatly in excess of EGF in the circulation.
Treatment of MT] carcinoma for 29 days with anti-EGF IgG
In a preliminary experiment to determine the effect of anti-EGF IgG on growth of MT1, two groups, each of five mice, were inoculated i.p. with 5 x 103 MT1 tumour cells; one group was given 2.5 mg of sheep anti-EGF IgG i.p. on alternate days starting 3 days after inoculation of tumour cells and the second group was left untreated. On day 29 of the experiment the first mouse in the control group was becoming moribund and the experiment was terminated at this time. All of the mice were killed and autopsied. The findings are summarised in Table V and demonstrate that the antibody exerted a pronounced growth-inhibitory effect. sheep IgG (1O ) or anti-EGF IgG (M) using the regimen described in the legend to Table V. The chart shows the times at which individual animals in each group were killed because of tumour burden. Analysis of the data using Wilcoxon's rank correlation test showed that there was a significant difference between survival of either untreated or control IgG-treated animals vs anti-EGF IgG-treated animals (P<0.05).
Anti-tmnour effect of long-term treatment with anti-EGF IgG
Three groups of ten mice, inoculated with MT1 tumour cells as in the preceding experiment, received either (a) no treatment, (b) normal IgG from an unimmunised sheep or (c) sheep anti-EGF IgG. Three days after inoculation of the tumour cells, 2.5 mg of the immunoglobulins were injected into the peritoneal cavity on alternate days for 4 weeks. Unlike the preliminary experiment, survival of each individual mouse was followed. The experiment was terminated after 110 days when surviving animals were killed and autopsied. The outcome of the experiment is shown in Figure 4 . There was no significant difference in the rate of tumour development between the groups receiving no treatment or control IgG from a non-immunised sheep. In these two groups, morbidity from tumour burden first occurred at days 30 and 32 respectively and eight out of ten animals had to be killed as result of tumour growth by day 60. The remaining two animals in both of the groups were alive and free of tumours when killed 3 months later. In the group of mice which received the anti-EGF IgG, three animals in the group were killed between days 60 and 67 as a result of tumour growth; the remaining seven animals had to be killed because of their poor condition between days 83 and 95, but on autopsy no tumour could be detected and morbidity was found to be due to renal failure. Indeed, the kidneys were extensively damaged in all ten mice in this group, including the three that at autopsy contained some tumour. Histochemical examination of the damaged kidneys showed that the lesions were due to glomerular deposition of immune complexes containing sheep IgG; no such immune complex disease was found in mice that had received the non-immune sheep IgG (results not shown). When normal kidney sections were stained with the anti-EGF IgG, staining was seen in the distal tubules which have previously been found to be a site of EGF synthesis by in situ hybridisation (Salido et al., 1989) . These results suggest that the cause of the kidney damage was not due to the reaction of the antibody with EGF produced in the kidneys, A this occurs at a different site (i.e. the distal tubules), but rather from the immune complex deposition in the glomeruli. Although anti-EGF IgG treatment caused long-term kidney damage, the antibody had noimmiate effect on the production of EGF by the distal tubules in short-term experiments in which output of EGF in the urine was measured following a single i.p injection of 2.5 mg of antibody. the circulation and lodged at a distant site in the body. In previous studies, it has been shown that blood-borne cancer cells exhibit organ-seective tumour growth (Murphy et al., 1988) . Similarly, tumour outgrowth has been shown to occur preferentially at sites of wound healing, and it has been postulated that factors released by host cells into the inflammatory wound environment to promote healing also facilitate tumour growth (Skipper et a!., 1988 (Le et al., 1991 (Nakamura et al., 1989; Hwang et al., 1992) . Although activated macrophages have been shown to synthesise TGF-x (Madtes et al., 1988) , whether they produce EGF has not been cleary established. They do however, produce a related form of EGF, namely heparin-binding EGF (Higashiyama et al., 1991) ; cross-reactivity of our antibody with this ligand, or with other EGF receptor ligands such as amphiregulin (Shoyab et al., 1989) (Baselga el al., 1993 (Divgi et al., 1991) , the longterm toxicity of repeated administration of such antibodies to human subjects remains to be determined (see Baselga et al., 1993) . This work was supported by the Cancer Research Campaign, UK.
